Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.61 |
| ▸ | JAK3 | P52333 | 20/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12596475 | 0.82 | JAK2 (0.66) | JAK2JAK3FLT3 | |
| SCHEMBL13768361 | 0.81 | JAK2 (0.65) | JAK2JAK3 | |
| SCHEMBL21208764 | 0.79 | JAK2 (0.62) | JAK2JAK3 | |
| SCHEMBL12596465 | 0.79 | JAK2 (0.62) | JAK2JAK3FLT3 | |
| SCHEMBL16404558 | 0.78 | JAK2 (0.61) | JAK2JAK3FLT3 | |
| SCHEMBL12649037 | 0.76 | JAK2 (0.58) | JAK2JAK3FLT3 | |
| SCHEMBL13842334 | 0.76 | JAK2 (1.00) | JAK2JAK3FLT3 | |
| SCHEMBL3427015 | 0.74 | JAK2 (0.56) | JAK2JAK3FLT3 | |
| SCHEMBL12595822 | 0.71 | JAK2 (0.72) | JAK2JAK3 | |
| SCHEMBL12595768 | 0.71 | JAK2 (1.00) | JAK2JAK3FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937064-B2 | Pyrazolo[1,5-a]pyrimidines useful as JAK2 inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937064-B2 | Pyrazolo[1,5-a]pyrimidines useful as JAK2 inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937064-B2 | Pyrazolo[1,5-a]pyrimidines useful as JAK2 inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-20 | — | — | US | disclosed |
| US-20110118255-A1 | PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JAK2 INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118255-A1 | PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JAK2 INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-19 | — | — | US | disclosed |
| EP-2252618-A1 | PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009085913-A1 | PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118255-A1 | PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JAK2 INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885FLT3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.